Table of Contents
1 Table Of Contents
1.1 List of Tables
1.2 List of Figures
2 Targeted Therapeutics: Executive Summary
2.1 Failure of Conventional Therapies in Curing Chronic Diseases has Created High Unmet Needs
2.2 Expanded Indications Open up New Potential Patient Group
2.3 Sales Value of Key Small Molecule Drugs for Targeted Therapeutics is increasing Every Year
2.4 Regulatory Landscape for Targeted Therapeutics is Stringent, Leading to Time Lag between Research and Commercialization
3 Targeted Therapeutics: Introduction
3.1 GBI Research Guidance
4 Targeted Therapeutics: Overview
4.1 Introduction
4.2 Targeted Therapy is the Need of the Hour
4.2.1 High Side Effects and Toxic Effects of Conventional Therapy
4.2.2 Variable Efficacy Rate of Conventional Drugs at the Affected Site
4.2.3 Resistance Developed to Conventional Drugs Used to Treat Infections
4.3 Targeted Therapeutics Market Drivers and Restraints
4.3.1 Targeted Therapeutics Market Drivers
4.3.2 Targeted Therapeutics Market Restraints
5 Targeted Therapeutics: Major Types of Targeted Therapeutics
5.1 Small Molecules
5.1.1 Overview
5.2 Innovative Small Molecule Therapeutics Market Drivers and Restraints
5.2.1 Small Molecule Therapeutics Market Drivers
5.2.2 Innovative Small Molecule Therapeutics Market Restraints
5.2.3 Profiles of Key Pipeline Molecules
5.3 Proteins/Peptide Drugs
5.3.1 Overview
5.4 Proteins/Peptide Drugs Therapeutics Market Drivers and Restraints
5.4.1 Peptides/Protein Drug Therapeutics Market Drivers
5.4.2 Peptides/Protein Drug Therapeutics Market Restraints
5.4.3 Profiles of Key Pipeline Molecules
5.5 Monoclonal Antibodies (MAbs) and Antibody Like Structures
5.5.1 Overview
5.6 Monoclonal Antibody Therapeutics, Market Drivers and Restraints
5.6.1 Monoclonal Antibody Therapeutics Market Drivers
5.6.2 Global Monoclonal Antibody Market Restraints
5.6.3 Profiles of Key Pipeline Molecules (MAb)
5.7 RNA Interference
5.7.1 Overview
5.8 RNA Interference Therapeutics Market Drivers and Restraints
5.8.1 RNA Interference Therapeutics Market Drivers
5.8.2 RNA Interference Therapeutics Market Restraints
5.8.3 Profiles of Key Pipeline Molecules (RNA)
5.9 Stem Cell Therapies
5.9.1 Overview
5.10 Stem Cell Therapeutics Market Drivers and Restraints
5.10.1 Stem Cell Therapeutics Market Drivers
5.10.2 Stem Cell Therapeutics Market Restraints
5.10.3 Profile of Key Late Stage Therapies
5.11 Gene Therapy
5.11.1 Overview
5.12 Gene Therapy Market Drivers and Restraints
5.12.1 Gene Therapy Market Drivers
5.12.2 Gene Therapy Market Restraints
5.12.3 Key Pipeline Candidates
6 Targeted Therapeutics: Regulatory Landscape
6.1 The US Regulatory Landscape Scenario
6.1.1 National Institute for Health (NIH)
6.1.2 FDA
6.2 EU Regulatory Landscape Scenario
6.2.1 Committee for Advanced Therapies (CAT)
7 Targeted Therapeutics: Competitive Landscape
7.1 Antisoma
7.1.1 Overview
7.1.2 Key Deals
7.2 AVI BioPharma
7.2.1 Overview
7.2.2 Key Deals
7.3 Biogen
7.3.1 Overview
7.3.2 Key Deals
7.4 Cephalon
7.4.1 Overview
7.4.2 Key Deals
7.5 Eli Lilly
7.5.1 Overview
7.5.2 Key Deals
7.6 Forest Laboratories
7.6.1 Overview
7.6.2 Key Deals
7.7 Genmab
7.7.1 Overview
7.7.2 Key Deals
7.8 Gilead Sciences
7.8.1 Overview
7.8.2 Key Deals
7.9 Hoffmann La- Roche (Genentech)
7.9.1 Overview
7.9.2 Key Deals
7.10 Isis Pharmaceuticals
7.10.1 Overview
7.10.2 Key Deals
7.11 Johnson and Johnson (J&J)
7.11.1 Overview
7.11.2 Key Deals
7.12 Mesoblast Limited
7.12.1 Overview
7.12.2 Key Deals
7.13 Pfizer
7.13.1 Overview
7.13.2 Key Deals
7.14 UCB
7.14.1 Overview
7.14.2 Key Deals
8 Targeted Therapeutics Market – Appendix
8.1 Market Definitions
8.2 List of Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Primary Research
8.3.4 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources